Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASAM: Neoadjuvant and Adjuvant Encorafenib + Binimetinib for BRAF-mutant In-transit Melanoma Metastases
NL-OMON52356Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib, binimetinib and nivolumab in cutaneous melanoma (CM) and melanoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Pathologic response to neoadjuvant encorafenib + binimetinib. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on NL-OMON52356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52356.